Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2003
03/20/2003WO2003022300A1 Preventives/remedies for bone/joint diseases
03/20/2003WO2003022299A1 Genobix agonists and antagonists for use in the treatment of metabolic disorders
03/20/2003WO2003022297A1 Biodegradable implant comprising a polylactide polymer and a lh-rh analogue
03/20/2003WO2003022296A1 Method and composition for treating immune complex associated disorders
03/20/2003WO2003022288A1 Nutritional compositions for controlling blood glucose level
03/20/2003WO2003022255A2 Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
03/20/2003WO2003022246A1 Treating effects of excessive reactive oxygen species
03/20/2003WO2003022244A1 Vascular occlusion solid-phase agent with immobilised platelet binding agent
03/20/2003WO2003022243A2 Sustained release of microcrystalline peptide suspensions
03/20/2003WO2003022242A1 Preparation of sustained release pharmaceutical composition
03/20/2003WO2003022227A2 Antisense modulation of vascular endothelial growth factor receptor-1 expression
03/20/2003WO2003022226A2 Neurotrophic components of the adnf i complex
03/20/2003WO2003022225A2 Compositions comprising mixtures of therapeutic proteins and methods of producing the same
03/20/2003WO2003022224A2 Cox-2 function and wound healing
03/20/2003WO2003022222A2 Antisense modulation of protein kinase r expression
03/20/2003WO2003022218A2 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
03/20/2003WO2003022217A2 Treatment of excessive radiation (e.g. sunburn) exposure
03/20/2003WO2003022213A2 Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
03/20/2003WO2003022212A2 Anti-tumor effects of prostate carcinoma tumor antigen-1
03/20/2003WO2003022205A2 Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
03/20/2003WO2003022203A2 Products and methods for treating microbial infections
03/20/2003WO2003022202A2 Compositions and methods for treatment of cancer
03/20/2003WO2003022052A1 Method for expression of small rna molecules within a cell
03/20/2003WO2003009898A8 Treatment of hair follicle with neurokinin 1 receptor antagonists
03/20/2003WO2003004046A3 Use of xaa-pro peptidases for the treatment of substance p-related disorders
03/20/2003WO2003002175A3 Enhanced systemic absorption of intradermally delivered substances
03/20/2003WO2003000280A3 Abin-mediated hepatitis protection
03/20/2003WO2002100845A8 Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/20/2003WO2002100836A8 Compounds, compositions and methods for modulating beta-amyloid production
03/20/2003WO2002100331A3 Calcium phosphate delivery vehicles for osteoinductive proteins
03/20/2003WO2002099075A3 Prmts as modifiers of the p53 pathway and methods of use
03/20/2003WO2002098361A3 T cell induced tissue repair and regeneration
03/20/2003WO2002094342A3 Compositions for protein delivery via the pulmonary route
03/20/2003WO2002090545A9 Nucleic acid coding for the cgl1 polypeptide and diagnostic and therapeutic application of said nucleic acid and of the cgl1 polypeptide
03/20/2003WO2002090494A3 Isolation, characterization, cloning and use of a mushroom lectin
03/20/2003WO2002090379A8 Process for inactivating prions in lipoproteins
03/20/2003WO2002089732A3 Therapeutic compisitions and methods for the inhibition of angiogenesis
03/20/2003WO2002087509A3 Colloidal metal compositions and methods
03/20/2003WO2002086076A3 Polynucleotides and polypeptides associated with the nf-kb pathway
03/20/2003WO2002079404A3 Cytoskeleton-associated proteins
03/20/2003WO2002078672A3 Liposomal tumor necrosis factor compositions and methods
03/20/2003WO2002077290A9 Methods for modifying pharmacokinetics and bioavailability of exogenous compounds
03/20/2003WO2002072602A3 Somatostatin antagonists
03/20/2003WO2002072024A3 Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto
03/20/2003WO2002069908A3 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
03/20/2003WO2002066040A8 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
03/20/2003WO2002062989A3 Methods of light activated release 0f ligands from endosomes
03/20/2003WO2002060317A3 Compositions and methods for the therapy and diagnosis of pancreatic cancer
03/20/2003WO2002053760A3 Chimeric cytolytic viruses for cancer treatment
03/20/2003WO2002053733A3 Regulation of human b7-h2 protein
03/20/2003WO2002053171A3 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity
03/20/2003WO2002052269A3 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
03/20/2003WO2002046417A3 Adipocyte complement related protein zacrp3x2
03/20/2003WO2002040529A3 Diastereomeric peptides and pharmaceutical compositions comprising them
03/20/2003WO2002039996A3 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
03/20/2003WO2002038726A3 Paramyxovirus vector for gene transfer to the cardiovascular system
03/20/2003WO2002036166A8 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease
03/20/2003WO2002030444A3 Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery
03/20/2003WO2002029051A3 Human secretin receptor-like gpcr
03/20/2003WO2002028408A3 Compositions and methods for the transport of biologically active agents across cellular barriers
03/20/2003WO2002026932A9 Rna aptamers and methods for identifying the same
03/20/2003WO2002024884A3 Regulation of human serine palmitoyltransferase-like enzyme
03/20/2003WO2002022211A3 Reduction of the electrocardiographic ot interval
03/20/2003WO2002020736A3 Proteases
03/20/2003WO2002020718A9 Osteoclast-associated receptor
03/20/2003WO2002020032A9 Stat3 agonists and antagonists and therapeutic uses thereof
03/20/2003WO2002018423A9 Bioactive peptide for cell adhesion
03/20/2003WO2002017947A3 Use of t proteins for the differential characterization and treatment of lesions and tumors of the nervous system
03/20/2003WO2002012188B1 Indole compounds useful for the treatment of cancer
03/20/2003WO2002009641A9 Promyostatin peptides and methods of using same
03/20/2003WO2002008260A9 Bstp-ecg1 protein and related reagents and methods of use thereof
03/20/2003WO2002006312A3 Disease-associated gene
03/20/2003WO2002004520A3 Transporters and ion channels
03/20/2003WO2002004490A3 Lipid metabolism molecules
03/20/2003WO2001094386A3 Method for the extraction and the use of antibiotically effective peptides for treating infectious diseases
03/20/2003WO2001078894A3 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
03/20/2003WO2001074860A3 Methods of identifying integrin ligands using differential gene expression
03/20/2003WO2001072341A3 Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
03/20/2003WO2001070253A8 Use of mia in immunotherapy
03/20/2003US20030056240 Transgenic animal model for use in the treatment of diabetes
03/20/2003US20030056238 GABA B1A receptor disruptions, compositions and methods relating thereto
03/20/2003US20030056235 Inhibition of gene expression in cells; obtain celss, transform with ribonucleic acids, monitor and detect adjustment in gene expression, adjustment in gene expression indicates gene expression inhibition
03/20/2003US20030056231 Development of transgenic model for interventions in neurodegenerative diseases
03/20/2003US20030056229 Nucleotide sequences coding polypeptide for use in the treatment of leukemias, autoimmune and arthritic diseases
03/20/2003US20030055261 Compounds with growth hormone releasing properties
03/20/2003US20030055240 HPV specific oligonucleotides
03/20/2003US20030055237 Isolated human secreted proteins, nucleic acid molecules encoding secreted proteins and uses thereof
03/20/2003US20030055236 Secreted protein HKABT24
03/20/2003US20030055231 Nucleotide sequences coding polypeptides for use in the treatment, prevention and diagnosis of osteoarthritis and cancer
03/20/2003US20030055222 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/20/2003US20030055221 Flint polypeptide for use in the treatment of inflammatory disorders
03/20/2003US20030055220 Protein complex for use in the diagnosis and prevention of bacterial infections
03/20/2003US20030055218 Human receptor proteins; related reagents and methods
03/20/2003US20030055217 Peptides derived from STEAP1
03/20/2003US20030055216 Nucleotide sequences coding polypeptide for use in the treatment of tumors
03/20/2003US20030055213 Peptide for use in the treatment of hypertension, asthma, cerebral disorders, angina pectoris, kidney and heart disorders
03/20/2003US20030055072 Methods of inhibiting Pin1-associated states using a fredericamycin a compound
03/20/2003US20030055028 Administering two separate dosage forms of a topically active corticosteroid or a pharmaceutically active salt thereof for therapy ofinflammatory bowel disease and sufficient to reduce or eliminate side effects
03/20/2003US20030055020 Introducing ribonucleic acid (RNA) into cell in an amount sufficient to inhibit expression of target gene, wherein RNA comprises a double-stranded structure with an identical nucleotide sequence as compared to portion of target gene
03/20/2003US20030055019 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
1 ... 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 ... 3163